CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2) Therapy, which delivers high levels of dissolved oxygen directly to the ...
IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on improved treatment of Acute Myocardial Infarction (AMI), announced that the first patient has been ...
Newark Beth Israel Medical Center, an RWJBarnabas Health facility, now offers heart attack patients a minimally invasive, “cutting-edge” cardiac treatment. The health care provider announced Nov. 29 ...
CHELMSFORD, Mass., October 31, 2022--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated ...
Important Milestone Toward Bringing SSO 2 Therapy to the U.S. Market Simon Dixon, MBChB, chair of cardiovascular medicine at Beaumont Hospital Royal Oak and an investigator for this study, noted, “In ...
Henry Mayo Newhall Hospital is one of the first hospitals in Southern California to improve treatment of "widowmaker" heart ...
“There are thousands of patients annually who can benefit from SSO 2 Therapy, 4,5 and the new ICD-10-PCS code is a significant milestone in the evolution and external validation of that therapy," said ...
Fresh off receiving a PMA, TherOx is now in the process of being acquired by Zoll Medical, an Asahi Kasei Group Company. Additional terms of the deal were not disclosed. Irvine, CA-based TherOX is ...
TherOx, the maker of a device that could quickly salvage damaged heart tissue after a heart attack, is in the midst of a sizable equity round — its largest since it a failed IPO attempt during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results